share_log

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

HC Wainwright & Co.維持對theravance biopharma 的買入評級,將價格目標下調至15美元。
Benzinga ·  08/06 15:02  · 評級/大行評級

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $20 to $15.

HC Wainwright & Co.分析師Douglas Tsao維持對theravance biopharma(納斯達克:TBPH)的買入評級,將目標價從20美元下調至15美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論